TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11938826

Group type: EXPERIMENTAL
Intervention: Yixin Yidu Decoction (YXYDD)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Qidong Yixin Oral Liquid (QDYX)
Number of subjects: 76
Study: 9331138

Group type: EXPERIMENTAL
Intervention: EP (carboplatin AUC 6 IV over 30 to 60 minutes on day 1, etoposide 120 mg/m2 IV days 1 to 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EP plus paclitaxel (paclitaxel 200 mg/m2 IV 1-hour infusion on day 1, carboplatin AUC 6 IV over 30 to 60 minutes on day 1, etoposide 50/100 mg orally on alternating days 1 to 10)
Number of subjects: 0
Study: 8398579

Group type: EXPERIMENTAL
Intervention: Midazolam (MDZ) 0.15 mg kg‐1
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2946252

Group type: EXPERIMENTAL
Intervention: Atrovent
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 3281461

Group type: EXPERIMENTAL
Intervention: Cefotetan (1 gm single dose)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Cefoxitin (3 doses of 2 gm)
Number of subjects: 286
Study: 30654388

Group type: EXPERIMENTAL
Intervention: HBV/HCV coinfection
Number of subjects: 9621

Group type: EXPERIMENTAL
Intervention: HCV mono-infection
Number of subjects: 9621

Group type: COMPARATOR
Intervention: HBV monoinfection
Number of subjects: 9621

Group type: COMPARATOR
Intervention: HCV monoinfection
Number of subjects: 9621
Study: 30665517

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28128911

Group type: EXPERIMENTAL
Intervention: Emergency percutaneous nephrostomy
Number of subjects: 113

Group type: COMPARATOR
Intervention: Percutaneous nephrolithotomy
Number of subjects: 113
Study: 25451321

Group type: EXPERIMENTAL
Intervention: 17‐β estradiol 2mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 17‐β estradiol 2mg/day and terbutaline 5mg/day
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: propranolol 80mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 32
Study: 23262925

Group type: EXPERIMENTAL
Intervention: Surgical staples
Number of subjects: 398

Group type: COMPARATOR
Intervention: Absorbable suture
Number of subjects: 398
Study: 21646983

Group type: EXPERIMENTAL
Intervention: Team communication with patient-actor during simulated emergency
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Content of communication episodes with patient-actor
Number of subjects: 108
Study: 19704363

Group type: EXPERIMENTAL
Intervention: Anterior tab flap (ATF) myringoplasty
Number of subjects: 111

Group type: COMPARATOR
Intervention: Standard underlay (SU) myringoplasty
Number of subjects: 111
Study: 16725163

Group type: EXPERIMENTAL
Intervention: HCA (3 x 500 mg/day)
Number of subjects: 10

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 10
Study: 14711956

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (Fraxiparine)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no prophylaxis)
Number of subjects: 150
Study: 11346808

Group type: EXPERIMENTAL
Intervention: 20 microg parathyroid hormone (1-34)
Number of subjects: 1637

Group type: EXPERIMENTAL
Intervention: 40 microg parathyroid hormone (1-34)
Number of subjects: 1637

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1637
Study: 9423994

Group type: EXPERIMENTAL
Intervention: 0.4% benoxinate hydrochloride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no anesthetic instillation)
Number of subjects: 20
Study: 8424298

Group type: EXPERIMENTAL
Intervention: Deliberate hypotension induced by labetalol with isoflurane
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (normotensive anaesthesia)
Number of subjects: 41
Study: 3325488

Group type: EXPERIMENTAL
Intervention: Glucose polymers (3 g/kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Glucose infusion (euglycemic clamp)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Glucose infusion
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Carbohydrate ingestion
Number of subjects: 7
Study: 28252590

Group type: EXPERIMENTAL
Intervention: Cold plasma surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inductor of interferon synthesis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiviral and immunotropic drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaccination methods
Number of subjects: 0
Study: 27050701

Group type: EXPERIMENTAL
Intervention: Matrikine-based technology (MPC)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Traditional growth factors
Number of subjects: 133

Group type: COMPARATOR
Intervention: All test materials (including MPC and traditional growth factors)
Number of subjects: 133
Study: 25391431

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (two sessions/week)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Citicoline 300 mg/day (control)
Number of subjects: 216
Study: 23705885

Group type: EXPERIMENTAL
Intervention: Low-glycemic-load diet
Number of subjects: 17

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 17
Study: 21702232

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) 10 mg/Kg bodyweight twice a day for five days
Number of subjects: 122

Group type: COMPARATOR
Intervention: Metronidazole (MTZ) 15 mg/Kg bodyweight divided in three daily doses for five days
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Metronidazole (MTZ)
Number of subjects: 122
Study: 18986070

Group type: EXPERIMENTAL
Intervention: Viewing head orientation with different retinal eccentricities (up to 90 degrees)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viewing eye-gaze direction with different retinal eccentricities (up to 4 degrees)
Number of subjects: 0
Study: 17260197

Group type: EXPERIMENTAL
Intervention: SEM II plug
Number of subjects: 103

Group type: COMPARATOR
Intervention: C-plug
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: REX plug
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Smaller sizes of all 3 plug types
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Overall performance of all 3 plug types
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: SEM II vs REX
Number of subjects: 103
Study: 12826991

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) daily
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) targeted
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo daily
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo targeted
Number of subjects: 153
Study: 10053177

Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 993

Group type: EXPERIMENTAL
Intervention: Bupropion
Number of subjects: 993

Group type: EXPERIMENTAL
Intervention: Bupropion and nicotine patch
Number of subjects: 993

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 993

Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 993
Study: 8902432

Group type: EXPERIMENTAL
Intervention: hydroxy‐gli (1.5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 1745700

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) 100 mg/wk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) 300 mg/wk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 100 mg/wk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 300 mg/wk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (including ND and TE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (except ND 100 mg/wk)
Number of subjects: 0
Study: 7050643

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Haloperidol plus amitriptyline
Number of subjects: 140

Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Metoclopramide plus promethazine
Number of subjects: 140
Study: 31983409

Group type: EXPERIMENTAL
Intervention: Transanal endoscopic surgery (TES) in obese patients (BMI ≥30 kg/m2)
Number of subjects: 681

Group type: COMPARATOR
Intervention: Transanal endoscopic surgery (TES) in non-obese patients (BMI <30 kg/m2)
Number of subjects: 681
Study: 30465366

Group type: EXPERIMENTAL
Intervention: Pioglitazone (used for >=2 years)
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Other oral therapy or insulin therapy (used for >=2 years)
Number of subjects: 1168
Study: 26071208

Group type: EXPERIMENTAL
Intervention: TC-5619 5mg
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: TC-5619 50mg
Number of subjects: 477

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: TC-5619 (both doses)
Number of subjects: 477
Study: 24182413

Group type: EXPERIMENTAL
Intervention: GnRH‐agonist triggering and luteal support with oral estradiol (2 mg/8 hours) and vaginal progesterone (200 mg/12 hours)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: GnRH‐a and a daily dose of 150 IU of recombinant LH from oocyte pickup
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: GnRH‐a and a single bolus of 60 μg of recombinant hCG on oocyte pickup
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: GnRH‐a and three doses of 20 μg of recombinant hCG separated by 48 hours
Number of subjects: 25

Group type: COMPARATOR
Intervention: 250 μg of recombinant hCG for trigger and standard luteal support
Number of subjects: 25
Study: 23158484

Group type: EXPERIMENTAL
Intervention: Selenium supplementation (200 µg oral selenium yeast daily for 6 months)
Number of subjects: 134
Study: 20395679

Group type: EXPERIMENTAL
Intervention: MLC601 (Neuroaid)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 18792548

Group type: COMPARATOR
Intervention: Tretinoin gel 0.025% (RA) monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2%-tretinoin 0.025% gel (CLIN/RA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate gel 1.2% (CLIN) monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle gel (VEH)
Number of subjects: 0
Study: 16169792

Group type: EXPERIMENTAL
Intervention: Usual treatment plus patient education program (group B)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Usual treatment (group A)
Number of subjects: 69
Study: 12201327

Group type: EXPERIMENTAL
Intervention: 0.5% nonoxynol-9 (NX9) in Group A, n = 20
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 0.125% nonoxynol-9 (NX9) in Group B, n = 15
Number of subjects: 35
Study: 10212515

Group type: EXPERIMENTAL
Intervention: Mefloquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulfadoxine pyrimethamine (S-P)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chloroquine and S-P
Number of subjects: 0
Study: 8535036

Group type: EXPERIMENTAL
Intervention: Usual treatment with a brief cognitive‐behavioral intervention
Number of subjects: 139

Group type: COMPARATOR
Intervention: Usual treatment without a brief cognitive‐behavioral intervention
Number of subjects: 139
Study: 2692655

Group type: EXPERIMENTAL
Intervention: Postoperative radiation with 54 Gy to the remaining breast for five weeks
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Breast conserving surgery
Number of subjects: 263

Group type: COMPARATOR
Intervention: Modified radical mastectomy
Number of subjects: 263
Study: 1209444

Group type: EXPERIMENTAL
Intervention: 4 g of L‐ascorbic acid daily for 4 months
Number of subjects: 2

Group type: COMPARATOR
Intervention: 1 g of citric acid daily for 4 months
Number of subjects: 2
Study: 31941475

Group type: EXPERIMENTAL
Intervention: MyPEEPS Mobile intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delayed intervention condition
Number of subjects: 100
Study: 30548935

Group type: COMPARATOR
Intervention: sirolimus + low dose tacrolimus (Tac group)
Number of subjects: 132

Group type: COMPARATOR
Intervention: sirolimus + mycophenolate mofetil (MMF group)
Number of subjects: 132
Study: 27091641

Group type: EXPERIMENTAL
Intervention: Paravertebral blockade
Number of subjects: 60

Group type: COMPARATOR
Intervention: Serratus-intercostal plane blockade
Number of subjects: 60
Study: 24091445

Group type: EXPERIMENTAL
Intervention: Visual presentation of apprehension videos
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control videos
Number of subjects: 15
Study: 22853014

Group type: COMPARATOR
Intervention: Anastrozole alone (1 mg orally every day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of anastrozole and fulvestrant (500 mg intramuscularly on day 1, 250 mg on days 14 and 28, then monthly)
Number of subjects: 0
Study: 20833531

Group type: EXPERIMENTAL
Intervention: Epidural 5% magnesium sulphate
Number of subjects: 90

Group type: COMPARATOR
Intervention: Epidural 0.9% sodium chloride
Number of subjects: 90
Study: 18372075

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine in combination with carboplatin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intravenous vinorelbine in combination with carboplatin
Number of subjects: 61
Study: 16188788

Group type: EXPERIMENTAL
Intervention: Poractant
Number of subjects: 58

Group type: COMPARATOR
Intervention: Beractant
Number of subjects: 58
Study: 14709838

Group type: EXPERIMENTAL
Intervention: 0.5 microg of daily oral calcitriol for 28 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 0.5 microg of daily oral calcitriol for 24 weeks (after initial 28 days)
Number of subjects: 18
Study: 10587023

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and epirubicin (FE)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil and epirubicin + cisplatin (FEP)
Number of subjects: 122
Study: 1853618

Group type: EXPERIMENTAL
Intervention: Surgical face masks during operations
Number of subjects: 3088

Group type: COMPARATOR
Intervention: No surgical face masks during operations
Number of subjects: 3088
Study: 6346830

Group type: EXPERIMENTAL
Intervention: Quinine sulphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29891223

Group type: EXPERIMENTAL
Intervention: Probiotic (8 × 10^9 CFU/day)
Number of subjects: 60
Study: 29226465

Group type: EXPERIMENTAL
Intervention: Oxygen therapy at 6 L min‐1 for 6‐12 h
Number of subjects: 144

Group type: COMPARATOR
Intervention: Ambient air
Number of subjects: 144
Study: 26817716

Group type: EXPERIMENTAL
Intervention: Fish oil providing 0.7 g EPA+DHA/d
Number of subjects: 312

Group type: COMPARATOR
Intervention: Control oil
Number of subjects: 312
Study: 24518285

Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 555

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 555
Study: 23269883

Group type: EXPERIMENTAL
Intervention: Exercise group (EG, n = 36)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (CG, n = 29)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Exercise group (EG)
Number of subjects: 65
Study: 20079647

Group type: EXPERIMENTAL
Intervention: Active alternating pressure mattress (NIMBUS 3)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Reactive mattress overlay (ROHO)
Number of subjects: 16
Study: 17571254

Group type: EXPERIMENTAL
Intervention: Neoimmun capsules (200 mg cyclosporine A)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Neoimmun capsules after a fat-rich breakfast
Number of subjects: 12

Group type: COMPARATOR
Intervention: Neoral (200 mg cyclosporine A)
Number of subjects: 12
Study: 15860645

Group type: COMPARATOR
Intervention: Normoxia (breathing normal room air; Fi(O(2)) = 0.21)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hypoxia (breathing a normobaric hypoxic gas mixture; Fi(O(2)) = 0.14)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both Normoxia and Hypoxia
Number of subjects: 10
Study: 12107673

Group type: EXPERIMENTAL
Intervention: Peer-led tuition from second‐year student instructors
Number of subjects: 122

Group type: COMPARATOR
Intervention: Tuition delivered by clinical staff
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Peer-led tuition
Number of subjects: 122
Study: 9818105

Group type: EXPERIMENTAL
Intervention: isoflurane inhalation (MAC 1‐1.5)
Number of subjects: 40

Group type: COMPARATOR
Intervention: propofol i.v. (6‐12 mg.kg‐1.hr‐1)
Number of subjects: 40
Study: 7723543

Group type: EXPERIMENTAL
Intervention: Compassionate care from trained volunteers
Number of subjects: 133

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 133
Study: 2024541

Group type: EXPERIMENTAL
Intervention: Captopril (group A, n = 17)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Enalapril (group B, n = 16)
Number of subjects: 33
Study: 7030223

Group type: EXPERIMENTAL
Intervention: Milk supplement (1 pint of milk a day at half price)
Number of subjects: 951

Group type: COMPARATOR
Intervention: Control (no milk supplement)
Number of subjects: 951
Study: 30657334

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR)
Number of subjects: 109
Study: 28626102

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 μg/(kg·h) after a bolus infusion at 0.5 μg/kg for 10 min before anesthesia induction)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (normal saline infusion)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study: 26970838

Group type: EXPERIMENTAL
Intervention: Occlusive dressing
Number of subjects: 200

Group type: COMPARATOR
Intervention: Exposure dressing
Number of subjects: 200
Study: 25115871

Group type: EXPERIMENTAL
Intervention: Intravenous peramivir (600 mg once daily)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Intravenous peramivir
Number of subjects: 121
Study: 23240476

Group type: COMPARATOR
Intervention: Pentavalent rotavirus vaccine
Number of subjects: 1804

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1804
Study: 19653751

Group type: EXPERIMENTAL
Intervention: Virtual reality manipulation of visual feedback during limb movement
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Visual appearance and correspondence between visual and felt position of limbs
Number of subjects: 8
Study: 18095518

Group type: EXPERIMENTAL
Intervention: Warfarin (INR; range 2‐3) for the first three months, followed by ASA (100 mg/day)
Number of subjects: 75

Group type: COMPARATOR
Intervention: ASA alone (100 mg/day)
Number of subjects: 75
Study: 15912981

Group type: EXPERIMENTAL
Intervention: Cystic duct occlusion with titanium clips
Number of subjects: 105

Group type: COMPARATOR
Intervention: Cystic duct occlusion with knots (ligature)
Number of subjects: 105
Study: 11161544

Group type: COMPARATOR
Intervention: Nutrison Standard (NS)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Self‐selected diet (SSD)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nutrison Multi Fibre (NMF)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nutrison Multi Fibre (NMF) administered orally
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nutrison Multi Fibre (NMF) administered nasogastrically
Number of subjects: 16
Study: 9433337

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 628

Group type: EXPERIMENTAL
Intervention: Current medication discontinuation
Number of subjects: 628
Study: 7736475

Group type: EXPERIMENTAL
Intervention: Ultrafiltration
Number of subjects: 16

Group type: COMPARATOR
Intervention: Intravenous bolus furosemide (mean dose = 248 mg)
Number of subjects: 16
Study: 2283639

Group type: EXPERIMENTAL
Intervention: Thiazide therapy
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Glucose load
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Cholesterol
Number of subjects: 497
Study: 157150

Group type: EXPERIMENTAL
Intervention: Topically applied progesterone
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 38
Study: 31740272

Group type: EXPERIMENTAL
Intervention: Impella LP5.0 pump + IABP
Number of subjects: 15

Group type: COMPARATOR
Intervention: IABP
Number of subjects: 15
Study: 30955310

Group type: EXPERIMENTAL
Intervention: Lateral point group of thoracic paravertebral space (group A)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Medial point group of thoracic paravertebral space (group B)
Number of subjects: 90
Study: 27629070

Group type: EXPERIMENTAL
Intervention: ATV/r + 3TC
Number of subjects: 286

Group type: COMPARATOR
Intervention: ATV/r + 2NUCs
Number of subjects: 286
Study: 25475945

Group type: EXPERIMENTAL
Intervention: Transradial coronary angiography (RA‐CA)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control arm (non-cannulated RA)
Number of subjects: 50
Study: 23415888

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study: 21187189

Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid 1800 mg/d
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid 1200 mg/d
Number of subjects: 360

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 360
Study: 19900646

Group type: EXPERIMENTAL
Intervention: Comprehensive postdischarge care management intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Organized acute stroke department care with enhanced discharge planning
Number of subjects: 0
Study: 17195810

Group type: EXPERIMENTAL
Intervention: Navigated total knee arthroplasty
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Postoperative clinical scoring systems
Number of subjects: 120
Study: 15841606

Group type: EXPERIMENTAL
Intervention: qigong plus body awareness therapy (n = 19)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 36
Study: 11484961

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 on days 1, 8, and 15, and etoposide 80 mg/m2 on days 8, 9, and 10 of a 28-day cycle
Number of subjects: 42
Study: 9974228

Group type: EXPERIMENTAL
Intervention: Automated compensation for visual-motor misalignments
Number of subjects: 0

Group type: COMPARATOR
Intervention: No automated compensation
Number of subjects: 0
Study: 7982185

Group type: EXPERIMENTAL
Intervention: High dose intravenous bolus recombinant interleukin-2 (rIL-2)
Number of subjects: 199
Study: 2915184

Group type: EXPERIMENTAL
Intervention: Inhaled histamine
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no histamine)
Number of subjects: 6